>>Signaling Pathways>> Others>>Tulopafant (RP 59227)

Tulopafant (RP 59227)

Catalog No.GC32541

Tulopafant(RP 59227)는 혈소판 활성화 인자(PAF) 길항제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Tulopafant (RP 59227) Chemical Structure

Cas No.: 116289-53-3

Size 가격 재고 수량
1mg
US$534.00
재고 있음
5mg
US$1,057.00
재고 있음
10mg
US$1,801.00
재고 있음
20mg
US$3,171.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com


고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Tulopafant is a platelet activating factor (PAF) antagonist.

Preincubation of neutrophils with Tulopafant (RP 59227) results in a concentration-dependent decrease in chemiluminescence produced by PAF primed cells[1].

Tulopafant (RP 59227) effectively reduces myocardial infarct size and reduces the incidence of ischemia and reperfusion-induced arrhythmias in barbital-anesthetized dogs[1].Histological examination reveals marked diminution of both interstitial hemorrhage and deposition of platelet and granulocytes in capillaries of cardiac xenografts when recipient animals are pretreated with Tulopafant[2].

[1]. Auchampach JA, et al. Effect of the platelet-activating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function. Basic Res Cardiol. 1998 Oct;93(5):361-71. [2]. O'Hair DP, et al. Tulopafant, a PAF receptor antagonist, increases capillary patency and prolongs survival in discordant cardiac xenotransplants. J Lipid Mediat. 1993 May;7(1):79-84.

리뷰

Review for Tulopafant (RP 59227)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tulopafant (RP 59227)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.